Anticancer Therapies – Products
Predictive Oncology and Cancer Research Horizons Partnered To Develop of Cancer Drugs
Predictive Oncology Inc. together with Cancer Research Horizons, announce that they have partnered to drive the development of oncology drugs utilizing Predictive Oncology’s PEDAL™ platform.
SonALAsense Announces Completion of First Cohort in Phase 2 Study of Sonodynamic Therapy for Recurrent Glioblastoma
SonALAsense has announced that the first cohort in Sonodynamic Therapy (SDT)-202 was fully enrolled.
Terumo Blood and Cell Technologies’ Platelet Pooling Set Cleared by FDA
Terumo Blood and Cell Technologies has announced US Food and Drug Administration clearance and official launch of its IMUGARD(R)WB Platelet Pooling Set, which supports extended shelf life of whole blood-derived platelets from five days to seven days.
Akamis Bio, Parker Institute for Cancer Immunotherapy and Cancer Research Institute Expand Partnership
Akamis Bio has announced an expansion of its ongoing partnership with the Parker Institute for Cancer Immunotherapy to include a clinical collaboration with the Cancer Research Institute that will focus on advancing novel treatments for pancreatic cancer.
Personalis and Moderna Sign New Agreement To Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
The platform will be used to sequence genomic information from a patient’s tumor sample to identify the unique genetic mutations that are most likely to generate a tailored antitumor response.
Avacta Announces Successful Completion of Fourth Dose Escalation in Phase 1 Clinical Study
Avacta Group plc announces that AVA6000 continues to show a very favorable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial.
Potentiating CD16-Activated ADCC in CAR-NK Cell Therapy
Sino Biological has developed a panel of quality proteins and antibodies for CD16 and accompanying molecules to support CAR-NK cell therapy research.
Personalis and UCSF To Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer
Personalis has announced a collaboration with UC San Francisco that will deploy a personalized liquid biopsy-based research use only assay for a study of patients with colorectal cancer.
Actym Therapeutics Reports Preclinical Data Demonstrating ACTM-838’s Ability To Generate Anti-Tumor Immunity
Actym Therapeutics has announced that an abstract highlighting detailed preclinical data of its lead candidate, ACTM-838, was accepted for presentation at the Society for Immunotherapy of Cancer 37th Annual Meeting.
OncoHost To Present Proteomics-Based Biomarker Model for Clinical Benefit to Immunotherapy in NSCLC Patients at SITC 2022
OncoHost has developed a novel predictive model for clinical benefit of immune checkpoint inhibitor in non-small cell lung cancer patients.